Ichnos Glenmark Innovation (IGI), an alliance between Glenmark Pharma (BOM:532296, NSE:GLENMARK) and its wholly owned subsidiary Ichnos Glenmark Innovation, shared promising Phase 1 data for ISB 2001, a first-in-class trispecific antibody for relapsed/refractory multiple myeloma.

The TRIgnite-1 study showed a 74% overall response rate in heavily pretreated patients, with an 84% response in those without prior CAR-T or bispecific therapies.

ISB 2001 targets BCMA, CD38, and CD3 to boost immune attack on myeloma cells, showing deep, durable responses and a manageable safety profile. The US FDA granted it Fast Track status in May.

The study is moving to dose expansion to refine dosing and further evaluate effectiveness.